Corcept Therapeutics (CORT) Expected to Announce Earnings on Monday

Corcept Therapeutics (NASDAQ:CORT) is anticipated to release its Q1 2025 earnings data after the market closes on Monday, May 5th. Analysts expect Corcept Therapeutics to post earnings of $0.17 per share and revenue of $177.93 million for the quarter. Corcept Therapeutics has set its FY 2025 guidance at EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.11). The firm had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $72.77 on Friday. The stock has a fifty day moving average of $65.70 and a 200-day moving average of $59.99. The stock has a market cap of $7.68 billion, a PE ratio of 57.75 and a beta of 0.15. Corcept Therapeutics has a fifty-two week low of $23.02 and a fifty-two week high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. HC Wainwright increased their target price on shares of Corcept Therapeutics from $115.00 to $150.00 and gave the company a “buy” rating in a report on Monday, March 31st. StockNews.com lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Canaccord Genuity Group raised their target price on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the company a “buy” rating in a research note on Tuesday, April 1st. Truist Financial lifted their target price on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Finally, Piper Sandler lifted their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an “overweight” rating in a report on Thursday, April 3rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.25.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $68.08, for a total transaction of $149,776.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 18,303 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $60.69, for a total value of $1,110,809.07. Following the sale, the insider now directly owns 85,622 shares in the company, valued at approximately $5,196,399.18. This trade represents a 17.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 163,124 shares of company stock valued at $15,117,614 in the last ninety days. Corporate insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.